Name | Number of supported studies | Average coverage | |
---|---|---|---|
astrocyte | 9 studies | 35% ± 12% | |
oligodendrocyte precursor cell | 9 studies | 31% ± 15% | |
microglial cell | 8 studies | 26% ± 12% | |
endothelial cell | 5 studies | 33% ± 17% | |
interneuron | 5 studies | 29% ± 9% | |
neuron | 4 studies | 26% ± 6% | |
epithelial cell | 4 studies | 24% ± 8% | |
GABAergic neuron | 4 studies | 28% ± 8% | |
enterocyte | 3 studies | 23% ± 1% | |
GABAergic amacrine cell | 3 studies | 20% ± 4% | |
Mueller cell | 3 studies | 17% ± 1% | |
retina horizontal cell | 3 studies | 37% ± 8% | |
rod bipolar cell | 3 studies | 38% ± 8% | |
oligodendrocyte | 3 studies | 24% ± 8% |
Name | Number of supported studies | Average coverage | |
---|---|---|---|
brain | 6 studies | 26% ± 7% |
Tissue | GTEx Coverage | GTEx Average TPM | GTEx Number of samples | TCGA Coverage | TCGA Average TPM | TCGA Number of samples |
---|---|---|---|---|---|---|
prostate | 100% | 4543.65 | 245 / 245 | 100% | 108.04 | 502 / 502 |
brain | 99% | 1186.19 | 2628 / 2642 | 99% | 22.15 | 700 / 705 |
kidney | 100% | 1639.08 | 89 / 89 | 97% | 18.34 | 874 / 901 |
thymus | 98% | 729.41 | 642 / 653 | 97% | 22.11 | 587 / 605 |
intestine | 100% | 7964.04 | 966 / 966 | 71% | 11.31 | 375 / 527 |
bladder | 100% | 1799.38 | 21 / 21 | 71% | 10.80 | 356 / 504 |
lung | 89% | 501.76 | 517 / 578 | 71% | 8.37 | 824 / 1155 |
adrenal gland | 100% | 1082.95 | 258 / 258 | 55% | 6.08 | 127 / 230 |
uterus | 97% | 665.12 | 165 / 170 | 56% | 8.49 | 258 / 459 |
stomach | 91% | 1140.73 | 326 / 359 | 56% | 6.88 | 160 / 286 |
breast | 100% | 1179.82 | 458 / 459 | 45% | 5.16 | 502 / 1118 |
ovary | 57% | 275.82 | 103 / 180 | 84% | 13.26 | 360 / 430 |
pancreas | 30% | 127.78 | 97 / 328 | 86% | 10.57 | 153 / 178 |
esophagus | 74% | 1454.84 | 1066 / 1445 | 34% | 2.98 | 63 / 183 |
eye | 0% | 0 | 0 / 0 | 100% | 24.35 | 80 / 80 |
spleen | 100% | 1786.27 | 241 / 241 | 0% | 0 | 0 / 0 |
adipose | 99% | 984.80 | 1190 / 1204 | 0% | 0 | 0 / 0 |
skin | 60% | 521.00 | 1082 / 1809 | 32% | 3.20 | 151 / 472 |
liver | 31% | 148.16 | 71 / 226 | 44% | 6.29 | 177 / 406 |
tonsil | 0% | 0 | 0 / 0 | 33% | 3.24 | 15 / 45 |
heart | 31% | 119.52 | 270 / 861 | 0% | 0 | 0 / 0 |
lymph node | 0% | 0 | 0 / 0 | 28% | 4.98 | 8 / 29 |
blood vessel | 27% | 147.66 | 362 / 1335 | 0% | 0 | 0 / 0 |
muscle | 7% | 24.64 | 55 / 803 | 0% | 0 | 0 / 0 |
peripheral blood | 3% | 14.24 | 25 / 929 | 0% | 0 | 0 / 0 |
abdomen | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
bone marrow | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
diaphragm | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
gingiva | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
nasal cavity | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
nasopharynx | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
nose | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
placenta | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
spinal column | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
ureter | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 1 |
GO_0046069 | Biological process | cGMP catabolic process |
GO_0010613 | Biological process | positive regulation of cardiac muscle hypertrophy |
GO_0007165 | Biological process | signal transduction |
GO_0019933 | Biological process | cAMP-mediated signaling |
GO_0046068 | Biological process | cGMP metabolic process |
GO_1900273 | Biological process | positive regulation of long-term synaptic potentiation |
GO_2000178 | Biological process | negative regulation of neural precursor cell proliferation |
GO_0032587 | Cellular component | ruffle membrane |
GO_0005886 | Cellular component | plasma membrane |
GO_0048471 | Cellular component | perinuclear region of cytoplasm |
GO_0043204 | Cellular component | perikaryon |
GO_0042383 | Cellular component | sarcolemma |
GO_0005654 | Cellular component | nucleoplasm |
GO_0005794 | Cellular component | Golgi apparatus |
GO_0005783 | Cellular component | endoplasmic reticulum |
GO_0005829 | Cellular component | cytosol |
GO_0004114 | Molecular function | 3',5'-cyclic-nucleotide phosphodiesterase activity |
GO_0047555 | Molecular function | 3',5'-cyclic-GMP phosphodiesterase activity |
GO_0046872 | Molecular function | metal ion binding |
GO_0004115 | Molecular function | 3',5'-cyclic-AMP phosphodiesterase activity |
GO_0005515 | Molecular function | protein binding |
Gene name | PDE9A |
Protein name | Phosphodiesterase (EC 3.1.4.-) High affinity cGMP-specific 3',5'-cyclic phosphodiesterase 9A (EC 3.1.4.35) |
Synonyms | hCG_401272 |
Description | FUNCTION: Specifically hydrolyzes the second messenger cGMP, which is a key regulator of many important physiological processes. Highly specific: compared to other members of the cyclic nucleotide phosphodiesterase family, has the highest affinity and selectivity for cGMP . Specifically regulates natriuretic-peptide-dependent cGMP signaling in heart, acting as a regulator of cardiac hypertrophy in myocytes and muscle. Does not regulate nitric oxide-dependent cGMP in heart . Additional experiments are required to confirm whether its ability to hydrolyze natriuretic-peptide-dependent cGMP is specific to heart or is a general feature of the protein (Probable). In brain, involved in cognitive function, such as learning and long-term memory (By similarity). . |
Accessions | ENST00000398227.7 [O76083-9] ENST00000335440.10 [O76083-12] A0A0S2Z475 ENST00000398234.7 [O76083-6] ENST00000398232.7 [O76083-13] ENST00000349112.7 [O76083-4] ENST00000398224.3 [O76083-3] ENST00000398236.7 [O76083-8] ENST00000398225.7 [O76083-14] ENST00000328862.10 [O76083-15] ENST00000291539.11 [O76083-1] O76083 ENST00000335512.8 [O76083-2] A0A0S2Z4T6 ENST00000380328.6 [O76083-5] ENST00000398229.7 [O76083-11] A0A0S2Z4A3 |